.GAMMA.-AMINOBUTYRIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C4H9NO2
Molecular Weight	103.1198
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NCCCC(O)=O

InChI

InChIKey=BTCSSZJGUNDROE-UHFFFAOYSA-N

InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)

HIDE SMILES / InChI

Molecular Formula	C4H9NO2
Molecular Weight	103.1198
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

γ-aminobutyric acid (GABA), a naturally occurring substance, which is a product of decarboxylation of the amino acid glutamate mediated by the synthesizing enzyme glutamic acid decarboxylase. GABA is a major inhibitory neurotransmitter of the brain and acts mainly through the GABAA receptor (GABAAR). GABA is locally produced by the pancreatic beta cells. GABAARs are also expressed in various immune cells, including T-cells, peripheral blood mononuclear cells, and are known to exert immune-inhibitory effects. Recently was studied, that GABA has the potential in treatment of Type I Diabetes. Moreover, was shown, that GABA administration could enhance immunity under stress conditions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; anion channel 202	Agonist 2,678		200.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Type 1 diabetes mellitus 17	Primary	Phase II 1,132	Unknown
Stress 11	Primary	Phase I 428	Unknown
Partial Seizures 3	Preventing	Not Provided 504	THERAPENTIN-90
Vascular diseases of the brain 3	Primary	Approved 8,429	Gammalon
Atherosclerosis of cerebral arteries 3	Primary	Approved 8,429	Gammalon
Chronic cerebrovascular insufficiency 3	Primary	Approved 8,429	Gammalon

PubMed

Show entries

Title	Date	PubMed
gamma-Aminobutyric acid in brain: its formation from glutamic acid.	1950 Nov	14794689
Mechanisms of action of antiepileptic drugs.	2005	15638774
Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.	2007 Oct 15	17942900

Showing 1 to 3 of 3 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.

Route of Administration: Oral

In Vitro Use Guide

The HEK293 cells constitutively expressing exogenous GABA receptor π subunit (GABRP) revealed the growth-promoting effect of GABA treatment (serial concentrations: 0, 1, 10, 100 μmol/L);for 6 d). GABA treatment stimulated GABRP-positive pancreatic ductal adenocarcinoma (PDAC) cell proliferatio and activated the mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/Erk) cascade. These findings imply that GABA and GABRP could play important roles in PDAC development and progression, and that this pathway can be a promising molecular target for the development of new therapeutic strategies for PDAC.